{"protocolSection": {"identificationModule": {"nctId": "NCT01425801", "orgStudyIdInfo": {"id": "M/100977/202"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Single Dose Study to Assess Efficacy, Safety and Tolerability of LAS100977 in Asthmatic Patients.", "officialTitle": "A Phase IIa, Randomised, Single Dose, Double-blind, Double-dummy, 6 Way Complete Cross-over, Placebo Controlled Clinical Trial to Assess the Efficacy, Safety and Tolerability of 4 Doses of LAS100977 QD Compared to Placebo and an Active Comparator in Patients With Persistent Asthma."}, "statusModule": {"statusVerifiedDate": "2018-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-08-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2012-02-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-02-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-08-29", "studyFirstSubmitQcDate": "2011-08-29", "studyFirstPostDateStruct": {"date": "2011-08-30", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-02-27", "resultsFirstSubmitQcDate": "2017-06-08", "resultsFirstPostDateStruct": {"date": "2018-01-26", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-05-07", "lastUpdatePostDateStruct": {"date": "2018-05-08", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the pharmacodynamics of single doses of inhaled LAS100977 QD in patients with persistent asthma."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["COPD"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 62, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "LAS100977 0.625 \u03bcg", "type": "EXPERIMENTAL", "description": "Single-dose LAS100977 0.625 \u03bcg, during double-blind treatment period", "interventionNames": ["Drug: LAS100977 0.625 \u03bcg", "Drug: Salbutamol placebo"]}, {"label": "LAS100977 1.25 \u03bcg", "type": "EXPERIMENTAL", "description": "Single-dose LAS100977 1.25 \u03bcg, during double-blind treatment period", "interventionNames": ["Drug: LAS100977 1.25 \u03bcg", "Drug: Salbutamol placebo"]}, {"label": "LAS100977 2.5 \u03bcg", "type": "EXPERIMENTAL", "description": "Single-dose LAS100977 2.5 \u03bcg, during double-blind treatment period", "interventionNames": ["Drug: LAS100977 2.5 \u03bcg", "Drug: Salbutamol placebo"]}, {"label": "Salbutamol", "type": "ACTIVE_COMPARATOR", "description": "Single-dose salbutamol 400 \u03bcg, during double-blind treatment period", "interventionNames": ["Drug: Salbutamol 400 \u03bcg", "Drug: LAS100977 placebo"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo to LAS100977, and placebo to salbutamol", "interventionNames": ["Drug: Salbutamol placebo", "Drug: LAS100977 placebo"]}, {"label": "LAS100977 0.313 \u03bcg", "type": "EXPERIMENTAL", "description": "Single-dose LAS100977 0.313 \u03bcg, during double-blind treatment period", "interventionNames": ["Drug: LAS100977 0.313 \u03bcg", "Drug: Salbutamol placebo"]}], "interventions": [{"type": "DRUG", "name": "LAS100977 0.313 \u03bcg", "description": "Dry powder inhalation, once-daily, single-dose", "armGroupLabels": ["LAS100977 0.313 \u03bcg"]}, {"type": "DRUG", "name": "LAS100977 0.625 \u03bcg", "description": "Dry powder inhalation, once-daily, single-dose", "armGroupLabels": ["LAS100977 0.625 \u03bcg"]}, {"type": "DRUG", "name": "LAS100977 1.25 \u03bcg", "description": "Dry powder inhalation, once-daily, single-dose", "armGroupLabels": ["LAS100977 1.25 \u03bcg"]}, {"type": "DRUG", "name": "LAS100977 2.5 \u03bcg", "description": "Dry powder inhalation, once-daily, single-dose", "armGroupLabels": ["LAS100977 2.5 \u03bcg"]}, {"type": "DRUG", "name": "Salbutamol 400 \u03bcg", "description": "Pressurized inhalation suspension, once-daily, single-dose", "armGroupLabels": ["Salbutamol"]}, {"type": "DRUG", "name": "Salbutamol placebo", "description": "Pressurized inhalation, once-daily", "armGroupLabels": ["LAS100977 0.313 \u03bcg", "LAS100977 0.625 \u03bcg", "LAS100977 1.25 \u03bcg", "LAS100977 2.5 \u03bcg", "Placebo"]}, {"type": "DRUG", "name": "LAS100977 placebo", "description": "Dry powder inhalation, once-daily", "armGroupLabels": ["Placebo", "Salbutamol"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1)", "description": "Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.", "timeFrame": "Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h post-dose"}], "secondaryOutcomes": [{"measure": "Percentage Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1)", "description": "Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.", "timeFrame": "Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h post-dose"}, {"measure": "Peak Forced Expiratory Volume in One Second (FEV1)", "description": "The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning on Day 1. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.", "timeFrame": "+15 min, +30 min, +1 h, +2 h, +3 h, +4 h post-dose"}, {"measure": "Time to Peak Forced Expiratory Volume in One Second (FEV1)", "description": "The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.", "timeFrame": "+15 min, +30 min, +1 h, +2 h, +3 h, +4 h post-dose"}, {"measure": "Change From Baseline to Trough Forced Expiratory Volume in One Second (FEV1)", "description": "Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). Trough at Day 2 was computed as the average of the two values measured at 23 and 24 hours after administration of the morning dose of investigational medicinal product on Day 1. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.", "timeFrame": "Baseline and +23 h and +24 h post-dose"}, {"measure": "Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) 0-24h at Day 1", "description": "FEV1 was normalized to baseline. Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.", "timeFrame": "Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h and +24 h"}, {"measure": "Absolute Values of Forced Expiratory Volume (FEV1) at Each Timepoint", "description": "Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.", "timeFrame": "Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h, +24 h, and +36 h"}, {"measure": "Change From Baseline in Forced Expiratory Volume (FEV1) at Each Timepoint", "description": "Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.", "timeFrame": "Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h, +24 h, and +36 h"}, {"measure": "Percentage Change From Baseline in Forced Expiratory Volume (FEV1) at Each Timepoint", "description": "Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.", "timeFrame": "Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h, +24 h, and +36 h"}, {"measure": "Change From Baseline in Peak Forced Vital Capacity (FVC)", "description": "Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.", "timeFrame": "Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h post-dose"}, {"measure": "Peak Forced Vital Capacity (FVC)", "description": "The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.", "timeFrame": "+15 min, +30 min, +1 h, +2 h, +3 h, +4 h"}, {"measure": "Time to Peak Forced Vital Capacity (FVC)", "description": "The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.", "timeFrame": "+15 min, +30 min, +1 h, +2 h, +3 h, +4 h"}, {"measure": "Change From Baseline to Trough Forced Vital Capacity (FVC)", "description": "Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). Trough at Day 2 was computed as the average of the two values measured at 23 and 24 hours after administration of the morning dose of investigational medicinal product on Day 1. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.", "timeFrame": "Baseline and +23 h +24 h post-dose"}, {"measure": "Change From Baseline in Normalized Forced Vital Capacity (FVC) Area Under the Curve (AUC)", "description": "FVC was normalized to baseline. Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.", "timeFrame": "Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h and +24 h"}, {"measure": "Absolute Values of Forced Vital Capacity (FVC) at Each Timepoint", "description": "Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.", "timeFrame": "Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h, +24 h, and +36 h"}, {"measure": "Change From Baseline in Forced Vital Capacity (FVC) at Each Timepoint", "description": "Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.", "timeFrame": "Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h, +24 h, and +36 h"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Adult male and female patients aged 18-70 years (both included).\n2. Clinical diagnosis of persistent asthma (according to GINA guidelines 2009 update) for at least 6 months prior to screening.\n3. Screening FEV1 value of 60% \\< FEV1 \u2264 85% of the predicted normal value.\n4. FEV1 reversibility \u2265 12% and an absolute increase of at least 200 ml over baseline value after inhalation of 400\u00b5g (four inhalations) of salbutamol.\n5. Pre-dose FEV1 value of first treatment period within the range of \u00b1 20% of the FEV1 measured at screening prior to salbutamol inhalation.\n6. Patients on a stable dose and regimen\n\nExclusion Criteria:\n\n1. Current smokers, former smokers within the last 6 months, or ex-smokers with a history of more than 10 pack-years.\n2. Patients diagnosed with COPD.\n3. Recent Respiratory tract infections within 6 weeks before Screening Visit.\n4. Intubation (ever) or hospitalization for longer than 24 hours for the management of an asthma exacerbation within the preceding 6 weeks of the screening visit.\n5. Clinically significant respiratory conditions.\n6. Clinically significant cardiovascular conditions.\n7. Patients unable to properly use a dry powder or pMDI inhaler device or unable to perform acceptable spirometry.\n8. Clinically relevant abnormalities laboratory, ECG parameters or physical examination results at the screening evaluation that in the investigator's opinion, preclude study participation.\n9. Patients who intend to use any concomitant medication not permitted by this protocol or who have not undergone the required washout period for a particular prohibited medication.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Carol Astbury, PhD", "affiliation": "AstraZeneca", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Almirall Investigational Sites#6", "city": "Berlin", "zip": "10117", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Almirall Investigational Sites#4", "city": "Berlin", "zip": "14050", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Almirall Investigational Sites#1", "city": "Berlin", "zip": "14057", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Almirall Investigational Sites#3", "city": "Frankfurt", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Almirall Investigational Sites#2", "city": "Grosshansdorf", "zip": "22927", "country": "Germany", "geoPoint": {"lat": 53.66667, "lon": 10.28333}}, {"facility": "Almirall Investigational Sites#8", "city": "Hamburg", "zip": "20249", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Almirall Investigational Sites#5", "city": "Wiesbaden", "zip": "65187", "country": "Germany", "geoPoint": {"lat": 50.08258, "lon": 8.24932}}, {"facility": "Almirall Investigational Sites#2", "city": "London", "zip": "W1G 8HT", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Almirall Investigational Sites#1", "city": "Manchester", "zip": "M3 9QZ", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}]}, "referencesModule": {"references": [{"pmid": "25398689", "type": "DERIVED", "citation": "Singh D, Pujol H, Ribera A, Seoane B, Massana E, Astbury C, Ruiz S, de Miquel G. A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting beta2-adrenergic agonist, in asthma; a Phase II, randomized study. BMC Pulm Med. 2014 Nov 14;14:176. doi: 10.1186/1471-2466-14-176."}], "seeAlsoLinks": [{"label": "Synopsis-M-100977-202", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3968&filename=Synopsis-M-100977-202-Final.pdf"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Screening took place 12-16 days before randomization. After screening, eligible patients entered a run-in period to assess clinical stability. A total of 115 patients were screened; 62 patients were assessed as eligible and randomized; 53 were not randomized due to screening failure (primarily non-fulfillment of inclusion/exclusion criteria)", "recruitmentDetails": "The study was conducted in 10 sites in Germany and United Kingdom, 9 of which randomized patients", "groups": [{"id": "FG000", "title": "Sequence A", "description": "Salbutamol 400 \u03bcg - LAS100977 0.313 \u03bcg - Placebo - LAS100977 0.625 \u03bcg - LAS100977 2.5 \u03bcg - LAS100977 1.25 \u03bcg"}, {"id": "FG001", "title": "Sequence B", "description": "LAS100977 0.313 \u03bcg - LAS100977 0.625 \u03bcg - Salbutamol 400 \u03bcg - LAS100977 1.25 \u03bcg - Placebo - LAS100977 2.5 \u03bcg"}, {"id": "FG002", "title": "Sequence C", "description": "LAS100977 0.625 \u03bcg - LAS100977 1.25 \u03bcg - LAS100977 0.313 \u03bcg - LAS100977 2.5 \u03bcg - Salbutamol 400 \u03bcg - Placebo"}, {"id": "FG003", "title": "Sequence D", "description": "LAS100977 1.25 \u03bcg - LAS100977 2.5 \u03bcg - LAS100977 0.625 \u03bcg - Placebo - LAS100977 0.313 \u03bcg - Salbutamol 400 \u03bcg"}, {"id": "FG004", "title": "Sequence E", "description": "LAS100977 2.5 \u03bcg - Placebo - LAS100977 1.25 \u03bcg - Salbutamol 400 \u03bcg - LAS100977 0.625 \u03bcg - LAS100977 0.313 \u03bcg"}, {"id": "FG005", "title": "Sequence F", "description": "Placebo - Salbutamol 400 \u03bcg - LAS100977 2.5 \u03bcg - LAS100977 0.313 \u03bcg - LAS100977 1.25 \u03bcg - LAS100977 0.625 \u03bcg"}], "periods": [{"title": "Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "12"}, {"groupId": "FG004", "numSubjects": "13"}, {"groupId": "FG005", "numSubjects": "10"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "12"}, {"groupId": "FG004", "numSubjects": "12"}, {"groupId": "FG005", "numSubjects": "10"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "12"}, {"groupId": "FG004", "numSubjects": "12"}, {"groupId": "FG005", "numSubjects": "10"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "12"}, {"groupId": "FG004", "numSubjects": "11"}, {"groupId": "FG005", "numSubjects": "10"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Period 3", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "12"}, {"groupId": "FG004", "numSubjects": "11"}, {"groupId": "FG005", "numSubjects": "10"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "12"}, {"groupId": "FG004", "numSubjects": "11"}, {"groupId": "FG005", "numSubjects": "10"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Stability criteria not fullfilled", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Period 4", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "12"}, {"groupId": "FG004", "numSubjects": "11"}, {"groupId": "FG005", "numSubjects": "10"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "12"}, {"groupId": "FG004", "numSubjects": "11"}, {"groupId": "FG005", "numSubjects": "10"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Not able to maintain visit schedule", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Period 5", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "12"}, {"groupId": "FG004", "numSubjects": "11"}, {"groupId": "FG005", "numSubjects": "10"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "12"}, {"groupId": "FG004", "numSubjects": "11"}, {"groupId": "FG005", "numSubjects": "10"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Period 6", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "12"}, {"groupId": "FG004", "numSubjects": "11"}, {"groupId": "FG005", "numSubjects": "10"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "12"}, {"groupId": "FG004", "numSubjects": "11"}, {"groupId": "FG005", "numSubjects": "10"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Overall Population", "description": "Safety population defined as all patients who were randomized and received at least one dose of investigational medicinal product"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "62"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "40.9", "spread": "11.2"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "22"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "40"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1)", "description": "Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.", "populationDescription": "ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h post-dose", "groups": [{"id": "OG000", "title": "Placebo", "description": "Dry powder administered via the Genuair\u00ae inhaler or pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}, {"id": "OG001", "title": "LAS100977 0.313 \u03bcg", "description": "Dry powder administered via the Genuair\u00ae inhaler"}, {"id": "OG002", "title": "LAS100977 0.625 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG003", "title": "LAS100977 1.25 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG004", "title": "LAS100977 2.5 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG005", "title": "Salbutamol 400 \u03bcg", "description": "Pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.202", "spread": "0.045"}, {"groupId": "OG001", "value": "0.477", "spread": "0.045"}, {"groupId": "OG002", "value": "0.524", "spread": "0.045"}, {"groupId": "OG003", "value": "0.573", "spread": "0.045"}, {"groupId": "OG004", "value": "0.608", "spread": "0.045"}, {"groupId": "OG005", "value": "0.555", "spread": "0.045"}]}]}], "analyses": [{"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Sequence, treatment and period as fixed effect factors, patient within sequence as random effect and baseline peak FEV1 at each period as a covariate", "paramType": "Least Squares Mean DIfference", "paramValue": "0.405", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.353", "ciUpperLimit": "0.458", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.027"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Sequence, treatment and period as fixed effect factors, patient within sequence as random effect and baseline peak FEV1 at each period as a covariate", "paramType": "Least Squares Mean Difference", "paramValue": "0.371", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.318", "ciUpperLimit": "0.424", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.027"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Sequence, treatment and period as fixed effect factors, patient within sequence as random effect and baseline peak FEV1 at each period as a covariate", "paramType": "Least Squares Mean Difference", "paramValue": "0.322", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.269", "ciUpperLimit": "0.375", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.027"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Sequence, treatment and period as fixed effect factors, patient within sequence as random effect and baseline peak FEV1 at each period as a covariate", "paramType": "Least Squares Mean Difference", "paramValue": "0.274", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.221", "ciUpperLimit": "0.327", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.027"}]}, {"type": "SECONDARY", "title": "Percentage Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1)", "description": "Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.", "populationDescription": "ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h post-dose", "groups": [{"id": "OG000", "title": "Placebo", "description": "Dry powder administered via the Genuair\u00ae inhaler or pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}, {"id": "OG001", "title": "LAS100977 0.313 \u03bcg", "description": "Dry powder administered via the Genuair\u00ae inhaler"}, {"id": "OG002", "title": "LAS100977 0.625 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG003", "title": "LAS100977 1.25 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG004", "title": "LAS100977 2.5 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG005", "title": "Salbutamol 400 \u03bcg", "description": "Pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.555", "spread": "1.655"}, {"groupId": "OG001", "value": "18.282", "spread": "1.651"}, {"groupId": "OG002", "value": "20.212", "spread": "1.651"}, {"groupId": "OG003", "value": "21.809", "spread": "1.651"}, {"groupId": "OG004", "value": "23.077", "spread": "1.650"}, {"groupId": "OG005", "value": "21.374", "spread": "1.658"}]}]}]}, {"type": "SECONDARY", "title": "Peak Forced Expiratory Volume in One Second (FEV1)", "description": "The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning on Day 1. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.", "populationDescription": "ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "+15 min, +30 min, +1 h, +2 h, +3 h, +4 h post-dose", "groups": [{"id": "OG000", "title": "Placebo", "description": "Dry powder administered via the Genuair\u00ae inhaler or pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}, {"id": "OG001", "title": "LAS100977 0.313 \u03bcg", "description": "Dry powder administered via the Genuair\u00ae inhaler"}, {"id": "OG002", "title": "LAS100977 0.625 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG003", "title": "LAS100977 1.25 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG004", "title": "LAS100977 2.5 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG005", "title": "Salbutamol 400 \u03bcg", "description": "Pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.855", "spread": "0.045"}, {"groupId": "OG001", "value": "3.129", "spread": "0.045"}, {"groupId": "OG002", "value": "3.177", "spread": "0.045"}, {"groupId": "OG003", "value": "3.225", "spread": "0.045"}, {"groupId": "OG004", "value": "3.260", "spread": "0.045"}, {"groupId": "OG005", "value": "3.207", "spread": "0.045"}]}]}]}, {"type": "SECONDARY", "title": "Time to Peak Forced Expiratory Volume in One Second (FEV1)", "description": "The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.", "populationDescription": "ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Hours", "timeFrame": "+15 min, +30 min, +1 h, +2 h, +3 h, +4 h post-dose", "groups": [{"id": "OG000", "title": "Placebo", "description": "Dry powder administered via the Genuair\u00ae inhaler or pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}, {"id": "OG001", "title": "LAS100977 0.313 \u03bcg", "description": "Dry powder administered via the Genuair\u00ae inhaler"}, {"id": "OG002", "title": "LAS100977 0.625 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG003", "title": "LAS100977 1.25 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG004", "title": "LAS100977 2.5 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG005", "title": "Salbutamol 400 \u03bcg", "description": "Pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.3", "spread": "1.3"}, {"groupId": "OG001", "value": "2.6", "spread": "1.3"}, {"groupId": "OG002", "value": "3.0", "spread": "1.1"}, {"groupId": "OG003", "value": "3.1", "spread": "0.9"}, {"groupId": "OG004", "value": "3.0", "spread": "1.1"}, {"groupId": "OG005", "value": "1.1", "spread": "0.8"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Trough Forced Expiratory Volume in One Second (FEV1)", "description": "Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). Trough at Day 2 was computed as the average of the two values measured at 23 and 24 hours after administration of the morning dose of investigational medicinal product on Day 1. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.", "populationDescription": "Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Baseline and +23 h and +24 h post-dose", "groups": [{"id": "OG000", "title": "Placebo", "description": "Dry powder administered via the Genuair\u00ae inhaler or pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}, {"id": "OG001", "title": "LAS100977 0.313 \u03bcg", "description": "Dry powder administered via the Genuair\u00ae inhaler"}, {"id": "OG002", "title": "LAS100977 0.625 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG003", "title": "LAS100977 1.25 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG004", "title": "LAS100977 2.5 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG005", "title": "Salbutamol 400 \u03bcg", "description": "Pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "58"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.054", "spread": "0.039"}, {"groupId": "OG001", "value": "0.166", "spread": "0.039"}, {"groupId": "OG002", "value": "0.205", "spread": "0.039"}, {"groupId": "OG003", "value": "0.278", "spread": "0.039"}, {"groupId": "OG004", "value": "0.346", "spread": "0.039"}, {"groupId": "OG005", "value": "-0.076", "spread": "0.039"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) 0-24h at Day 1", "description": "FEV1 was normalized to baseline. Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.", "populationDescription": "Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h and +24 h", "groups": [{"id": "OG000", "title": "Placebo", "description": "Dry powder administered via the Genuair\u00ae inhaler or pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}, {"id": "OG001", "title": "LAS100977 0.313 \u03bcg", "description": "Dry powder administered via the Genuair\u00ae inhaler"}, {"id": "OG002", "title": "LAS100977 0.625 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG003", "title": "LAS100977 1.25 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG004", "title": "LAS100977 2.5 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG005", "title": "Salbutamol 400 \u03bcg", "description": "Pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "59"}, {"groupId": "OG005", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.007", "spread": "0.039"}, {"groupId": "OG001", "value": "0.282", "spread": "0.039"}, {"groupId": "OG002", "value": "0.321", "spread": "0.038"}, {"groupId": "OG003", "value": "0.390", "spread": "0.038"}, {"groupId": "OG004", "value": "0.446", "spread": "0.039"}, {"groupId": "OG005", "value": "0.100", "spread": "0.039"}]}]}]}, {"type": "SECONDARY", "title": "Absolute Values of Forced Expiratory Volume (FEV1) at Each Timepoint", "description": "Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.", "populationDescription": "Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h, +24 h, and +36 h", "groups": [{"id": "OG000", "title": "Placebo", "description": "Dry powder administered via the Genuair\u00ae inhaler or pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}, {"id": "OG001", "title": "LAS100977 0.313 \u03bcg", "description": "Dry powder administered via the Genuair\u00ae inhaler"}, {"id": "OG002", "title": "LAS100977 0.625 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG003", "title": "LAS100977 1.25 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG004", "title": "LAS100977 2.5 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG005", "title": "Salbutamol 400 \u03bcg", "description": "Pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "classes": [{"title": "0.25 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.696", "spread": "0.030"}, {"groupId": "OG001", "value": "2.863", "spread": "0.030"}, {"groupId": "OG002", "value": "2.886", "spread": "0.030"}, {"groupId": "OG003", "value": "2.934", "spread": "0.030"}, {"groupId": "OG004", "value": "3.007", "spread": "0.030"}, {"groupId": "OG005", "value": "3.106", "spread": "0.030"}]}]}, {"title": "1 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.719", "spread": "0.037"}, {"groupId": "OG001", "value": "3.000", "spread": "0.037"}, {"groupId": "OG002", "value": "3.025", "spread": "0.037"}, {"groupId": "OG003", "value": "3.098", "spread": "0.037"}, {"groupId": "OG004", "value": "3.133", "spread": "0.037"}, {"groupId": "OG005", "value": "3.147", "spread": "0.037"}]}]}, {"title": "2 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.746", "spread": "0.039"}, {"groupId": "OG001", "value": "3.034", "spread": "0.038"}, {"groupId": "OG002", "value": "3.081", "spread": "0.038"}, {"groupId": "OG003", "value": "3.136", "spread": "0.038"}, {"groupId": "OG004", "value": "3.188", "spread": "0.039"}, {"groupId": "OG005", "value": "3.123", "spread": "0.039"}]}]}, {"title": "3 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "59"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.771", "spread": "0.041"}, {"groupId": "OG001", "value": "3.069", "spread": "0.041"}, {"groupId": "OG002", "value": "3.102", "spread": "0.041"}, {"groupId": "OG003", "value": "3.190", "spread": "0.041"}, {"groupId": "OG004", "value": "3.196", "spread": "0.041"}, {"groupId": "OG005", "value": "3.040", "spread": "0.041"}]}]}, {"title": "4 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.774", "spread": "0.044"}, {"groupId": "OG001", "value": "3.058", "spread": "0.044"}, {"groupId": "OG002", "value": "3.124", "spread": "0.044"}, {"groupId": "OG003", "value": "3.167", "spread": "0.044"}, {"groupId": "OG004", "value": "3.211", "spread": "0.044"}, {"groupId": "OG005", "value": "2.937", "spread": "0.044"}]}]}, {"title": "6 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.722", "spread": "0.038"}, {"groupId": "OG001", "value": "3.008", "spread": "0.038"}, {"groupId": "OG002", "value": "3.087", "spread": "0.038"}, {"groupId": "OG003", "value": "3.157", "spread": "0.038"}, {"groupId": "OG004", "value": "3.194", "spread": "0.038"}, {"groupId": "OG005", "value": "2.812", "spread": "0.038"}]}]}, {"title": "8 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.715", "spread": "0.040"}, {"groupId": "OG001", "value": "3.033", "spread": "0.039"}, {"groupId": "OG002", "value": "3.062", "spread": "0.039"}, {"groupId": "OG003", "value": "3.139", "spread": "0.039"}, {"groupId": "OG004", "value": "3.180", "spread": "0.039"}, {"groupId": "OG005", "value": "2.772", "spread": "0.039"}]}]}, {"title": "12 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "56"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.659", "spread": "0.044"}, {"groupId": "OG001", "value": "2.943", "spread": "0.043"}, {"groupId": "OG002", "value": "2.980", "spread": "0.043"}, {"groupId": "OG003", "value": "3.035", "spread": "0.043"}, {"groupId": "OG004", "value": "3.111", "spread": "0.043"}, {"groupId": "OG005", "value": "2.669", "spread": "0.044"}]}]}, {"title": "14 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "59"}, {"groupId": "OG005", "value": "53"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.597", "spread": "0.042"}, {"groupId": "OG001", "value": "2.903", "spread": "0.041"}, {"groupId": "OG002", "value": "2.941", "spread": "0.041"}, {"groupId": "OG003", "value": "3.018", "spread": "0.041"}, {"groupId": "OG004", "value": "3.094", "spread": "0.042"}, {"groupId": "OG005", "value": "2.683", "spread": "0.043"}]}]}, {"title": "23 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.588", "spread": "0.040"}, {"groupId": "OG001", "value": "2.804", "spread": "0.039"}, {"groupId": "OG002", "value": "2.836", "spread": "0.040"}, {"groupId": "OG003", "value": "2.923", "spread": "0.040"}, {"groupId": "OG004", "value": "2.985", "spread": "0.040"}, {"groupId": "OG005", "value": "2.562", "spread": "0.040"}]}]}, {"title": "24 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "59"}, {"groupId": "OG003", "value": "59"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.618", "spread": "0.040"}, {"groupId": "OG001", "value": "2.840", "spread": "0.039"}, {"groupId": "OG002", "value": "2.890", "spread": "0.040"}, {"groupId": "OG003", "value": "2.948", "spread": "0.040"}, {"groupId": "OG004", "value": "3.019", "spread": "0.040"}, {"groupId": "OG005", "value": "2.605", "spread": "0.040"}]}]}, {"title": "36 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.689", "spread": "0.042"}, {"groupId": "OG001", "value": "2.823", "spread": "0.041"}, {"groupId": "OG002", "value": "2.798", "spread": "0.041"}, {"groupId": "OG003", "value": "2.892", "spread": "0.041"}, {"groupId": "OG004", "value": "2.929", "spread": "0.041"}, {"groupId": "OG005", "value": "2.690", "spread": "0.041"}]}]}, {"title": "0.5 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.723", "spread": "0.034"}, {"groupId": "OG001", "value": "2.956", "spread": "0.033"}, {"groupId": "OG002", "value": "2.972", "spread": "0.033"}, {"groupId": "OG003", "value": "3.033", "spread": "0.033"}, {"groupId": "OG004", "value": "3.089", "spread": "0.033"}, {"groupId": "OG005", "value": "3.142", "spread": "0.034"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Forced Expiratory Volume (FEV1) at Each Timepoint", "description": "Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.", "populationDescription": "Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h, +24 h, and +36 h", "groups": [{"id": "OG000", "title": "Placebo", "description": "Dry powder administered via the Genuair\u00ae inhaler or pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}, {"id": "OG001", "title": "LAS100977 0.313 \u03bcg", "description": "Dry powder administered via the Genuair\u00ae inhaler"}, {"id": "OG002", "title": "LAS100977 0.625 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG003", "title": "LAS100977 1.25 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG004", "title": "LAS100977 2.5 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG005", "title": "Salbutamol 400 \u03bcg", "description": "Pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "classes": [{"title": "0.25 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.048", "spread": "0.030"}, {"groupId": "OG001", "value": "0.214", "spread": "0.030"}, {"groupId": "OG002", "value": "0.237", "spread": "0.030"}, {"groupId": "OG003", "value": "0.285", "spread": "0.030"}, {"groupId": "OG004", "value": "0.358", "spread": "0.030"}, {"groupId": "OG005", "value": "0.457", "spread": "0.030"}]}]}, {"title": "0.5 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.071", "spread": "0.034"}, {"groupId": "OG001", "value": "0.304", "spread": "0.033"}, {"groupId": "OG002", "value": "0.319", "spread": "0.033"}, {"groupId": "OG003", "value": "0.381", "spread": "0.033"}, {"groupId": "OG004", "value": "0.437", "spread": "0.033"}, {"groupId": "OG005", "value": "0.490", "spread": "0.034"}]}]}, {"title": "1 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.067", "spread": "0.037"}, {"groupId": "OG001", "value": "0.348", "spread": "0.037"}, {"groupId": "OG002", "value": "0.373", "spread": "0.037"}, {"groupId": "OG003", "value": "0.446", "spread": "0.037"}, {"groupId": "OG004", "value": "0.481", "spread": "0.037"}, {"groupId": "OG005", "value": "0.495", "spread": "0.037"}]}]}, {"title": "2 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.094", "spread": "0.039"}, {"groupId": "OG001", "value": "0.382", "spread": "0.038"}, {"groupId": "OG002", "value": "0.429", "spread": "0.038"}, {"groupId": "OG003", "value": "0.484", "spread": "0.038"}, {"groupId": "OG004", "value": "0.536", "spread": "0.039"}, {"groupId": "OG005", "value": "0.471", "spread": "0.039"}]}]}, {"title": "3 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "59"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.119", "spread": "0.041"}, {"groupId": "OG001", "value": "0.416", "spread": "0.041"}, {"groupId": "OG002", "value": "0.450", "spread": "0.041"}, {"groupId": "OG003", "value": "0.537", "spread": "0.041"}, {"groupId": "OG004", "value": "0.543", "spread": "0.041"}, {"groupId": "OG005", "value": "0.388", "spread": "0.041"}]}]}, {"title": "4 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.121", "spread": "0.044"}, {"groupId": "OG001", "value": "0.406", "spread": "0.044"}, {"groupId": "OG002", "value": "0.471", "spread": "0.044"}, {"groupId": "OG003", "value": "0.515", "spread": "0.044"}, {"groupId": "OG004", "value": "0.558", "spread": "0.044"}, {"groupId": "OG005", "value": "0.284", "spread": "0.044"}]}]}, {"title": "6 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.067", "spread": "0.038"}, {"groupId": "OG001", "value": "0.353", "spread": "0.038"}, {"groupId": "OG002", "value": "0.432", "spread": "0.038"}, {"groupId": "OG003", "value": "0.501", "spread": "0.038"}, {"groupId": "OG004", "value": "0.539", "spread": "0.038"}, {"groupId": "OG005", "value": "0.157", "spread": "0.038"}]}]}, {"title": "8 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.056", "spread": "0.040"}, {"groupId": "OG001", "value": "0.374", "spread": "0.039"}, {"groupId": "OG002", "value": "0.403", "spread": "0.039"}, {"groupId": "OG003", "value": "0.480", "spread": "0.039"}, {"groupId": "OG004", "value": "0.521", "spread": "0.039"}, {"groupId": "OG005", "value": "0.113", "spread": "0.039"}]}]}, {"title": "12 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "56"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.005", "spread": "0.044"}, {"groupId": "OG001", "value": "0.288", "spread": "0.043"}, {"groupId": "OG002", "value": "0.326", "spread": "0.043"}, {"groupId": "OG003", "value": "0.380", "spread": "0.043"}, {"groupId": "OG004", "value": "0.456", "spread": "0.043"}, {"groupId": "OG005", "value": "0.014", "spread": "0.044"}]}]}, {"title": "14 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "59"}, {"groupId": "OG005", "value": "53"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.053", "spread": "0.042"}, {"groupId": "OG001", "value": "0.253", "spread": "0.041"}, {"groupId": "OG002", "value": "0.291", "spread": "0.041"}, {"groupId": "OG003", "value": "0.367", "spread": "0.041"}, {"groupId": "OG004", "value": "0.443", "spread": "0.042"}, {"groupId": "OG005", "value": "0.032", "spread": "0.043"}]}]}, {"title": "23 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.067", "spread": "0.040"}, {"groupId": "OG001", "value": "0.148", "spread": "0.039"}, {"groupId": "OG002", "value": "0.181", "spread": "0.040"}, {"groupId": "OG003", "value": "0.268", "spread": "0.040"}, {"groupId": "OG004", "value": "0.330", "spread": "0.040"}, {"groupId": "OG005", "value": "-0.093", "spread": "0.040"}]}]}, {"title": "24 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "59"}, {"groupId": "OG003", "value": "59"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.040", "spread": "0.040"}, {"groupId": "OG001", "value": "0.183", "spread": "0.039"}, {"groupId": "OG002", "value": "0.233", "spread": "0.040"}, {"groupId": "OG003", "value": "0.291", "spread": "0.040"}, {"groupId": "OG004", "value": "0.362", "spread": "0.040"}, {"groupId": "OG005", "value": "-0.052", "spread": "0.040"}]}]}, {"title": "36 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.035", "spread": "0.042"}, {"groupId": "OG001", "value": "0.169", "spread": "0.041"}, {"groupId": "OG002", "value": "0.144", "spread": "0.041"}, {"groupId": "OG003", "value": "0.238", "spread": "0.041"}, {"groupId": "OG004", "value": "0.275", "spread": "0.041"}, {"groupId": "OG005", "value": "0.036", "spread": "0.041"}]}]}]}, {"type": "SECONDARY", "title": "Percentage Change From Baseline in Forced Expiratory Volume (FEV1) at Each Timepoint", "description": "Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.", "populationDescription": "Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h, +24 h, and +36 h", "groups": [{"id": "OG000", "title": "Placebo", "description": "Dry powder administered via the Genuair\u00ae inhaler or pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}, {"id": "OG001", "title": "LAS100977 0.313 \u03bcg", "description": "Dry powder administered via the Genuair\u00ae inhaler"}, {"id": "OG002", "title": "LAS100977 0.625 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG003", "title": "LAS100977 1.25 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG004", "title": "LAS100977 2.5 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG005", "title": "Salbutamol 400 \u03bcg", "description": "Pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "classes": [{"title": "0.25 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.519", "spread": "1.090"}, {"groupId": "OG001", "value": "8.325", "spread": "1.084"}, {"groupId": "OG002", "value": "8.846", "spread": "1.084"}, {"groupId": "OG003", "value": "10.789", "spread": "1.084"}, {"groupId": "OG004", "value": "13.511", "spread": "1.081"}, {"groupId": "OG005", "value": "17.744", "spread": "1.098"}]}]}, {"title": "0.5 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.449", "spread": "1.205"}, {"groupId": "OG001", "value": "11.757", "spread": "1.199"}, {"groupId": "OG002", "value": "12.006", "spread": "1.199"}, {"groupId": "OG003", "value": "14.362", "spread": "1.199"}, {"groupId": "OG004", "value": "16.715", "spread": "1.196"}, {"groupId": "OG005", "value": "18.806", "spread": "12.209"}]}]}, {"title": "1 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.407", "spread": "1.356"}, {"groupId": "OG001", "value": "13.452", "spread": "1.350"}, {"groupId": "OG002", "value": "14.307", "spread": "1.350"}, {"groupId": "OG003", "value": "16.927", "spread": "1.350"}, {"groupId": "OG004", "value": "18.336", "spread": "1.352"}, {"groupId": "OG005", "value": "19.085", "spread": "1.360"}]}]}, {"title": "2 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.520", "spread": "1.434"}, {"groupId": "OG001", "value": "14.741", "spread": "1.427"}, {"groupId": "OG002", "value": "16.371", "spread": "1.428"}, {"groupId": "OG003", "value": "18.509", "spread": "1.428"}, {"groupId": "OG004", "value": "20.226", "spread": "1.430"}, {"groupId": "OG005", "value": "17.755", "spread": "1.438"}]}]}, {"title": "3 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "59"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.435", "spread": "1.479"}, {"groupId": "OG001", "value": "15.965", "spread": "1.472"}, {"groupId": "OG002", "value": "17.190", "spread": "1.472"}, {"groupId": "OG003", "value": "20.357", "spread": "1.477"}, {"groupId": "OG004", "value": "20.550", "spread": "1.470"}, {"groupId": "OG005", "value": "14.537", "spread": "1.484"}]}]}, {"title": "4 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.288", "spread": "1.596"}, {"groupId": "OG001", "value": "15.400", "spread": "1.589"}, {"groupId": "OG002", "value": "17.960", "spread": "1.590"}, {"groupId": "OG003", "value": "19.454", "spread": "1.590"}, {"groupId": "OG004", "value": "21.155", "spread": "1.587"}, {"groupId": "OG005", "value": "10.608", "spread": "1.600"}]}]}, {"title": "6 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.682", "spread": "1.439"}, {"groupId": "OG001", "value": "13.661", "spread": "1.424"}, {"groupId": "OG002", "value": "16.490", "spread": "1.425"}, {"groupId": "OG003", "value": "19.080", "spread": "1.425"}, {"groupId": "OG004", "value": "20.612", "spread": "1.421"}, {"groupId": "OG005", "value": "5.796", "spread": "1.438"}]}]}, {"title": "8 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.752", "spread": "1.505"}, {"groupId": "OG001", "value": "14.118", "spread": "1.482"}, {"groupId": "OG002", "value": "15.128", "spread": "1.482"}, {"groupId": "OG003", "value": "18.199", "spread": "1.482"}, {"groupId": "OG004", "value": "19.733", "spread": "1.478"}, {"groupId": "OG005", "value": "4.493", "spread": "1.497"}]}]}, {"title": "12 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "56"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.402", "spread": "1.627"}, {"groupId": "OG001", "value": "10.847", "spread": "1.614"}, {"groupId": "OG002", "value": "12.388", "spread": "1.614"}, {"groupId": "OG003", "value": "14.251", "spread": "1.614"}, {"groupId": "OG004", "value": "17.170", "spread": "1.616"}, {"groupId": "OG005", "value": "0.997", "spread": "1.639"}]}]}, {"title": "14 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "59"}, {"groupId": "OG005", "value": "53"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.903", "spread": "1.559"}, {"groupId": "OG001", "value": "9.427", "spread": "1.551"}, {"groupId": "OG002", "value": "11.008", "spread": "1.544"}, {"groupId": "OG003", "value": "11.771", "spread": "1.544"}, {"groupId": "OG004", "value": "16.716", "spread": "1.555"}, {"groupId": "OG005", "value": "1.892", "spread": "1.594"}]}]}, {"title": "23 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.117", "spread": "1.464"}, {"groupId": "OG001", "value": "5.451", "spread": "1.444"}, {"groupId": "OG002", "value": "6.955", "spread": "1.445"}, {"groupId": "OG003", "value": "9.893", "spread": "1.445"}, {"groupId": "OG004", "value": "12.375", "spread": "1.449"}, {"groupId": "OG005", "value": "-3.649", "spread": "1.464"}]}]}, {"title": "24 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "59"}, {"groupId": "OG003", "value": "59"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.611", "spread": "1.473"}, {"groupId": "OG001", "value": "7.084", "spread": "1.453"}, {"groupId": "OG002", "value": "8.918", "spread": "1.461"}, {"groupId": "OG003", "value": "10.975", "spread": "1.461"}, {"groupId": "OG004", "value": "13.716", "spread": "1.458"}, {"groupId": "OG005", "value": "-1.736", "spread": "1.482"}]}]}, {"title": "36 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.904", "spread": "1.574"}, {"groupId": "OG001", "value": "6.396", "spread": "1.554"}, {"groupId": "OG002", "value": "5.589", "spread": "1.555"}, {"groupId": "OG003", "value": "8.742", "spread": "1.555"}, {"groupId": "OG004", "value": "10.370", "spread": "1.558"}, {"groupId": "OG005", "value": "2.098", "spread": "1.572"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Peak Forced Vital Capacity (FVC)", "description": "Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.", "populationDescription": "ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h post-dose", "groups": [{"id": "OG000", "title": "Placebo", "description": "Dry powder administered via the Genuair\u00ae inhaler or pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}, {"id": "OG001", "title": "LAS100977 0.313 \u03bcg", "description": "Dry powder administered via the Genuair\u00ae inhaler"}, {"id": "OG002", "title": "LAS100977 0.625 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG003", "title": "LAS100977 1.25 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG004", "title": "LAS100977 2.5 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG005", "title": "Salbutamol 400 \u03bcg", "description": "Pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.222", "spread": "0.034"}, {"groupId": "OG001", "value": "0.317", "spread": "0.034"}, {"groupId": "OG002", "value": "0.329", "spread": "0.034"}, {"groupId": "OG003", "value": "0.361", "spread": "0.034"}, {"groupId": "OG004", "value": "0.380", "spread": "0.034"}, {"groupId": "OG005", "value": "0.361", "spread": "0.034"}]}]}]}, {"type": "SECONDARY", "title": "Peak Forced Vital Capacity (FVC)", "description": "The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.", "populationDescription": "ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "+15 min, +30 min, +1 h, +2 h, +3 h, +4 h", "groups": [{"id": "OG000", "title": "Placebo", "description": "Dry powder administered via the Genuair\u00ae inhaler or pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}, {"id": "OG001", "title": "LAS100977 0.313 \u03bcg", "description": "Dry powder administered via the Genuair\u00ae inhaler"}, {"id": "OG002", "title": "LAS100977 0.625 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG003", "title": "LAS100977 1.25 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG004", "title": "LAS100977 2.5 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG005", "title": "Salbutamol 400 \u03bcg", "description": "Pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.483", "spread": "0.034"}, {"groupId": "OG001", "value": "4.578", "spread": "0.034"}, {"groupId": "OG002", "value": "4.590", "spread": "0.034"}, {"groupId": "OG003", "value": "4.622", "spread": "0.034"}, {"groupId": "OG004", "value": "4.641", "spread": "0.034"}, {"groupId": "OG005", "value": "4.622", "spread": "0.034"}]}]}]}, {"type": "SECONDARY", "title": "Time to Peak Forced Vital Capacity (FVC)", "description": "The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.", "populationDescription": "ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Hours", "timeFrame": "+15 min, +30 min, +1 h, +2 h, +3 h, +4 h", "groups": [{"id": "OG000", "title": "Placebo", "description": "Dry powder administered via the Genuair\u00ae inhaler or pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}, {"id": "OG001", "title": "LAS100977 0.313 \u03bcg", "description": "Dry powder administered via the Genuair\u00ae inhaler"}, {"id": "OG002", "title": "LAS100977 0.625 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG003", "title": "LAS100977 1.25 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG004", "title": "LAS100977 2.5 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG005", "title": "Salbutamol 400 \u03bcg", "description": "Pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.1", "spread": "1.4"}, {"groupId": "OG001", "value": "1.8", "spread": "1.4"}, {"groupId": "OG002", "value": "2.3", "spread": "1.4"}, {"groupId": "OG003", "value": "2.1", "spread": "1.2"}, {"groupId": "OG004", "value": "2.2", "spread": "1.4"}, {"groupId": "OG005", "value": "1.5", "spread": "1.2"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Trough Forced Vital Capacity (FVC)", "description": "Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). Trough at Day 2 was computed as the average of the two values measured at 23 and 24 hours after administration of the morning dose of investigational medicinal product on Day 1. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.", "populationDescription": "Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Baseline and +23 h +24 h post-dose", "groups": [{"id": "OG000", "title": "Placebo", "description": "Dry powder administered via the Genuair\u00ae inhaler or pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}, {"id": "OG001", "title": "LAS100977 0.313 \u03bcg", "description": "Dry powder administered via the Genuair\u00ae inhaler"}, {"id": "OG002", "title": "LAS100977 0.625 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG003", "title": "LAS100977 1.25 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG004", "title": "LAS100977 2.5 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG005", "title": "Salbutamol 400 \u03bcg", "description": "Pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "58"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.028", "spread": "0.035"}, {"groupId": "OG001", "value": "0.094", "spread": "0.035"}, {"groupId": "OG002", "value": "0.050", "spread": "0.035"}, {"groupId": "OG003", "value": "0.111", "spread": "0.035"}, {"groupId": "OG004", "value": "0.120", "spread": "0.035"}, {"groupId": "OG005", "value": "-0.065", "spread": "0.035"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Normalized Forced Vital Capacity (FVC) Area Under the Curve (AUC)", "description": "FVC was normalized to baseline. Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.", "populationDescription": "Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h and +24 h", "groups": [{"id": "OG000", "title": "Placebo", "description": "Dry powder administered via the Genuair\u00ae inhaler or pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}, {"id": "OG001", "title": "LAS100977 0.313 \u03bcg", "description": "Dry powder administered via the Genuair\u00ae inhaler"}, {"id": "OG002", "title": "LAS100977 0.625 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG003", "title": "LAS100977 1.25 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG004", "title": "LAS100977 2.5 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG005", "title": "Salbutamol 400 \u03bcg", "description": "Pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "59"}, {"groupId": "OG005", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.017", "spread": "0.031"}, {"groupId": "OG001", "value": "0.135", "spread": "0.031"}, {"groupId": "OG002", "value": "0.109", "spread": "0.030"}, {"groupId": "OG003", "value": "0.169", "spread": "0.030"}, {"groupId": "OG004", "value": "0.192", "spread": "0.031"}, {"groupId": "OG005", "value": "0.054", "spread": "0.031"}]}]}]}, {"type": "SECONDARY", "title": "Absolute Values of Forced Vital Capacity (FVC) at Each Timepoint", "description": "Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.", "populationDescription": "Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h, +24 h, and +36 h", "groups": [{"id": "OG000", "title": "Placebo", "description": "Dry powder administered via the Genuair\u00ae inhaler or pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}, {"id": "OG001", "title": "LAS100977 0.313 \u03bcg", "description": "Dry powder administered via the Genuair\u00ae inhaler"}, {"id": "OG002", "title": "LAS100977 0.625 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG003", "title": "LAS100977 1.25 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG004", "title": "LAS100977 2.5 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG005", "title": "Salbutamol 400 \u03bcg", "description": "Pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "classes": [{"title": "0.25h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.295", "spread": "0.030"}, {"groupId": "OG001", "value": "4.420", "spread": "0.030"}, {"groupId": "OG002", "value": "4.368", "spread": "0.030"}, {"groupId": "OG003", "value": "4.383", "spread": "0.030"}, {"groupId": "OG004", "value": "4.417", "spread": "0.030"}, {"groupId": "OG005", "value": "4.471", "spread": "0.030"}]}]}, {"title": "0.5 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.320", "spread": "0.032"}, {"groupId": "OG001", "value": "4.458", "spread": "0.032"}, {"groupId": "OG002", "value": "4.405", "spread": "0.032"}, {"groupId": "OG003", "value": "4.438", "spread": "0.032"}, {"groupId": "OG004", "value": "4.443", "spread": "0.032"}, {"groupId": "OG005", "value": "4.502", "spread": "0.032"}]}]}, {"title": "1 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.295", "spread": "0.034"}, {"groupId": "OG001", "value": "4.442", "spread": "0.034"}, {"groupId": "OG002", "value": "4.429", "spread": "0.034"}, {"groupId": "OG003", "value": "4.480", "spread": "0.034"}, {"groupId": "OG004", "value": "4.498", "spread": "0.034"}, {"groupId": "OG005", "value": "4.502", "spread": "0.034"}]}]}, {"title": "2 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.321", "spread": "0.034"}, {"groupId": "OG001", "value": "4.445", "spread": "0.034"}, {"groupId": "OG002", "value": "4.444", "spread": "0.034"}, {"groupId": "OG003", "value": "4.495", "spread": "0.034"}, {"groupId": "OG004", "value": "4.512", "spread": "0.034"}, {"groupId": "OG005", "value": "4.477", "spread": "0.034"}]}]}, {"title": "3 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "59"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.352", "spread": "0.036"}, {"groupId": "OG001", "value": "4.462", "spread": "0.035"}, {"groupId": "OG002", "value": "4.472", "spread": "0.035"}, {"groupId": "OG003", "value": "4.505", "spread": "0.035"}, {"groupId": "OG004", "value": "4.505", "spread": "0.035"}, {"groupId": "OG005", "value": "4.454", "spread": "0.036"}]}]}, {"title": "4 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.316", "spread": "0.035"}, {"groupId": "OG001", "value": "4.459", "spread": "0.035"}, {"groupId": "OG002", "value": "4.462", "spread": "0.035"}, {"groupId": "OG003", "value": "4.463", "spread": "0.035"}, {"groupId": "OG004", "value": "4.517", "spread": "0.034"}, {"groupId": "OG005", "value": "4.398", "spread": "0.035"}]}]}, {"title": "6 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.322", "spread": "0.033"}, {"groupId": "OG001", "value": "4.413", "spread": "0.033"}, {"groupId": "OG002", "value": "1.411", "spread": "0.033"}, {"groupId": "OG003", "value": "4.464", "spread": "0.033"}, {"groupId": "OG004", "value": "4.513", "spread": "0.033"}, {"groupId": "OG005", "value": "4.360", "spread": "0.033"}]}]}, {"title": "8 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.325", "spread": "0.035"}, {"groupId": "OG001", "value": "4.456", "spread": "0.035"}, {"groupId": "OG002", "value": "4.412", "spread": "0.035"}, {"groupId": "OG003", "value": "4.487", "spread": "0.035"}, {"groupId": "OG004", "value": "4.499", "spread": "0.035"}, {"groupId": "OG005", "value": "4.335", "spread": "0.035"}]}]}, {"title": "12 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "56"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.310", "spread": "0.036"}, {"groupId": "OG001", "value": "4.409", "spread": "0.036"}, {"groupId": "OG002", "value": "4.349", "spread": "0.036"}, {"groupId": "OG003", "value": "4.414", "spread": "0.036"}, {"groupId": "OG004", "value": "4.453", "spread": "0.036"}, {"groupId": "OG005", "value": "4.277", "spread": "0.037"}]}]}, {"title": "14 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "59"}, {"groupId": "OG005", "value": "53"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.235", "spread": "0.036"}, {"groupId": "OG001", "value": "4.357", "spread": "0.036"}, {"groupId": "OG002", "value": "4.360", "spread": "0.036"}, {"groupId": "OG003", "value": "4.436", "spread": "0.036"}, {"groupId": "OG004", "value": "4.458", "spread": "0.036"}, {"groupId": "OG005", "value": "4.269", "spread": "0.037"}]}]}, {"title": "23 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.244", "spread": "0.037"}, {"groupId": "OG001", "value": "4.366", "spread": "0.036"}, {"groupId": "OG002", "value": "4.303", "spread": "0.036"}, {"groupId": "OG003", "value": "4.375", "spread": "0.036"}, {"groupId": "OG004", "value": "4.367", "spread": "0.036"}, {"groupId": "OG005", "value": "4.223", "spread": "0.037"}]}]}, {"title": "24 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "59"}, {"groupId": "OG003", "value": "59"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.238", "spread": "0.038"}, {"groupId": "OG001", "value": "4.359", "spread": "0.037"}, {"groupId": "OG002", "value": "4.335", "spread": "0.038"}, {"groupId": "OG003", "value": "4.384", "spread": "0.038"}, {"groupId": "OG004", "value": "4.410", "spread": "0.038"}, {"groupId": "OG005", "value": "4.193", "spread": "0.038"}]}]}, {"title": "36 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.252", "spread": "0.040"}, {"groupId": "OG001", "value": "4.390", "spread": "0.039"}, {"groupId": "OG002", "value": "4.280", "spread": "0.039"}, {"groupId": "OG003", "value": "4.352", "spread": "0.039"}, {"groupId": "OG004", "value": "4.381", "spread": "0.039"}, {"groupId": "OG005", "value": "4.284", "spread": "0.040"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Forced Vital Capacity (FVC) at Each Timepoint", "description": "Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.", "populationDescription": "Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h, +24 h, and +36 h", "groups": [{"id": "OG000", "title": "Placebo", "description": "Dry powder administered via the Genuair\u00ae inhaler or pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}, {"id": "OG001", "title": "LAS100977 0.313 \u03bcg", "description": "Dry powder administered via the Genuair\u00ae inhaler"}, {"id": "OG002", "title": "LAS100977 0.625 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG003", "title": "LAS100977 1.25 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG004", "title": "LAS100977 2.5 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae"}, {"id": "OG005", "title": "Salbutamol 400 \u03bcg", "description": "Pressurised inhalation suspension administered via Ventolin Evohaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "classes": [{"title": "0.25 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.038", "spread": "0.030"}, {"groupId": "OG001", "value": "0.162", "spread": "0.030"}, {"groupId": "OG002", "value": "0.111", "spread": "0.030"}, {"groupId": "OG003", "value": "0.125", "spread": "0.030"}, {"groupId": "OG004", "value": "0.159", "spread": "0.030"}, {"groupId": "OG005", "value": "0.213", "spread": "0.030"}]}]}, {"title": "0.5 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.059", "spread": "0.032"}, {"groupId": "OG001", "value": "0.197", "spread": "0.032"}, {"groupId": "OG002", "value": "0.144", "spread": "0.032"}, {"groupId": "OG003", "value": "0.177", "spread": "0.032"}, {"groupId": "OG004", "value": "0.182", "spread": "0.032"}, {"groupId": "OG005", "value": "0.241", "spread": "0.032"}]}]}, {"title": "1 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.034", "spread": "0.034"}, {"groupId": "OG001", "value": "0.182", "spread": "0.034"}, {"groupId": "OG002", "value": "0.169", "spread": "0.034"}, {"groupId": "OG003", "value": "0.219", "spread": "0.034"}, {"groupId": "OG004", "value": "0.237", "spread": "0.034"}, {"groupId": "OG005", "value": "0.242", "spread": "0.034"}]}]}, {"title": "2 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.060", "spread": "0.034"}, {"groupId": "OG001", "value": "0.184", "spread": "0.034"}, {"groupId": "OG002", "value": "0.183", "spread": "0.034"}, {"groupId": "OG003", "value": "0.234", "spread": "0.034"}, {"groupId": "OG004", "value": "0.252", "spread": "0.034"}, {"groupId": "OG005", "value": "0.217", "spread": "0.034"}]}]}, {"title": "3 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "59"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.089", "spread": "0.036"}, {"groupId": "OG001", "value": "0.199", "spread": "0.035"}, {"groupId": "OG002", "value": "0.209", "spread": "0.035"}, {"groupId": "OG003", "value": "0.241", "spread": "0.035"}, {"groupId": "OG004", "value": "0.242", "spread": "0.035"}, {"groupId": "OG005", "value": "0.191", "spread": "0.036"}]}]}, {"title": "4 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.055", "spread": "0.035"}, {"groupId": "OG001", "value": "0.198", "spread": "0.035"}, {"groupId": "OG002", "value": "0.201", "spread": "0.035"}, {"groupId": "OG003", "value": "0.202", "spread": "0.035"}, {"groupId": "OG004", "value": "0.256", "spread": "0.034"}, {"groupId": "OG005", "value": "0.137", "spread": "0.035"}]}]}, {"title": "6 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.057", "spread": "0.033"}, {"groupId": "OG001", "value": "0.149", "spread": "0.033"}, {"groupId": "OG002", "value": "0.147", "spread": "0.033"}, {"groupId": "OG003", "value": "0.200", "spread": "0.033"}, {"groupId": "OG004", "value": "0.249", "spread": "0.033"}, {"groupId": "OG005", "value": "0.096", "spread": "0.033"}]}]}, {"title": "8 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.054", "spread": "0.035"}, {"groupId": "OG001", "value": "0.185", "spread": "0.035"}, {"groupId": "OG002", "value": "0.141", "spread": "0.035"}, {"groupId": "OG003", "value": "0.216", "spread": "0.035"}, {"groupId": "OG004", "value": "0.228", "spread": "0.035"}, {"groupId": "OG005", "value": "0.064", "spread": "0.035"}]}]}, {"title": "12 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "56"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.042", "spread": "0.036"}, {"groupId": "OG001", "value": "0.141", "spread": "0.036"}, {"groupId": "OG002", "value": "0.081", "spread": "0.036"}, {"groupId": "OG003", "value": "0.146", "spread": "0.036"}, {"groupId": "OG004", "value": "0.185", "spread": "0.036"}, {"groupId": "OG005", "value": "0.001", "spread": "0.037"}]}]}, {"title": "14 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "59"}, {"groupId": "OG005", "value": "53"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.027", "spread": "0.036"}, {"groupId": "OG001", "value": "0.095", "spread": "0.036"}, {"groupId": "OG002", "value": "0.097", "spread": "0.036"}, {"groupId": "OG003", "value": "0.173", "spread": "0.036"}, {"groupId": "OG004", "value": "0.195", "spread": "0.036"}, {"groupId": "OG005", "value": "0.006", "spread": "0.037"}]}]}, {"title": "23 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.022", "spread": "0.037"}, {"groupId": "OG001", "value": "0.101", "spread": "0.036"}, {"groupId": "OG002", "value": "0.038", "spread": "0.036"}, {"groupId": "OG003", "value": "0.110", "spread": "0.036"}, {"groupId": "OG004", "value": "0.102", "spread": "0.036"}, {"groupId": "OG005", "value": "-0.043", "spread": "0.037"}]}]}, {"title": "24 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "59"}, {"groupId": "OG003", "value": "59"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.034", "spread": "0.038"}, {"groupId": "OG001", "value": "0.086", "spread": "0.037"}, {"groupId": "OG002", "value": "0.063", "spread": "0.038"}, {"groupId": "OG003", "value": "0.111", "spread": "0.038"}, {"groupId": "OG004", "value": "0.137", "spread": "0.038"}, {"groupId": "OG005", "value": "-0.079", "spread": "0.038"}]}]}, {"title": "36 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "60"}, {"groupId": "OG005", "value": "58"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.011", "spread": "0.040"}, {"groupId": "OG001", "value": "0.128", "spread": "0.039"}, {"groupId": "OG002", "value": "0.018", "spread": "0.039"}, {"groupId": "OG003", "value": "0.089", "spread": "0.039"}, {"groupId": "OG004", "value": "0.118", "spread": "0.039"}, {"groupId": "OG005", "value": "0.022", "spread": "0.040"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 14 (\u00b12) days after last intake of investigational medicinal product", "description": "Safety population defined as all randomized patients who took at least 1 dose of investigational medicinal product The total number of patients in the safety population was 62; due to study drop-out and the crossover study design, not all patients received all treatments", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Dry powder administered via the Genuair\u00ae inhaler or pressurised inhalation suspension administered via Ventolin Evohaler\u00ae", "seriousNumAffected": 0, "seriousNumAtRisk": 59, "otherNumAffected": 8, "otherNumAtRisk": 59}, {"id": "EG001", "title": "LAS100977 0.313 \u03bcg", "description": "Dry powder administered via the Genuair\u00ae inhaler", "seriousNumAffected": 0, "seriousNumAtRisk": 60, "otherNumAffected": 12, "otherNumAtRisk": 60}, {"id": "EG002", "title": "LAS100977 0.625 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae", "seriousNumAffected": 0, "seriousNumAtRisk": 60, "otherNumAffected": 10, "otherNumAtRisk": 60}, {"id": "EG003", "title": "LAS100977 1.25 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae", "seriousNumAffected": 0, "seriousNumAtRisk": 60, "otherNumAffected": 12, "otherNumAtRisk": 60}, {"id": "EG004", "title": "LAS100977 2.5 \u03bcg", "description": "Dry powder for inhalation administered via Genuair\u00ae", "seriousNumAffected": 0, "seriousNumAtRisk": 61, "otherNumAffected": 9, "otherNumAtRisk": 61}, {"id": "EG005", "title": "Salbutamol 400 \u03bcg", "description": "Pressurised inhalation suspension administered via Ventolin Evohaler\u00ae", "seriousNumAffected": 0, "seriousNumAtRisk": 62, "otherNumAffected": 6, "otherNumAtRisk": 62}], "otherEvents": [{"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 59}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 60}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 60}, {"groupId": "EG003", "numAffected": 8, "numAtRisk": 60}, {"groupId": "EG004", "numAffected": 7, "numAtRisk": 61}, {"groupId": "EG005", "numAffected": 6, "numAtRisk": 62}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 59}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 60}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 60}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 60}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 61}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 62}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Publication and/or presentation whether complete or partial, of any part of the data or results of this trial will be subject to revision and written agreement between the investigator and sponsor"}, "pointOfContact": {"title": "Study Director", "organization": "AstraZeneca", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T4202", "name": "Oculocerebral Syndrome With Hypopigmentation", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000000420", "term": "Albuterol"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000015149", "term": "Tocolytic Agents"}, {"id": "D000012102", "term": "Reproductive Control Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M3767", "name": "Albuterol", "asFound": "Upper limb", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M17869", "name": "Tocolytic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}